The Role of Reimbursement in Healthcare Startup Success

Founders obsess over whether their therapy works and whether it will be approved. Far fewer think early enough about whether anyone will pay for it. Yet in healthcare, the reimbursement decision often determines commercial success more than the product itself. This essay explains the role of reimbursement in healthcare startup success. It is educational and is not investment advice.

The patient is rarely the payer

The defining feature of healthcare markets is that the person who receives a therapy is usually not the one who pays for it. Insurers and government programs stand between the product and the patient, and they decide whether and how much to cover. This means that approval and clinical value are not enough. A therapy must also win a separate decision, made by payers, about whether it is worth covering. Startups that plan only for regulatory approval and ignore this second gate are planning for half the journey.

Coverage is its own approval

Securing coverage is, in practice, a second approval that is as consequential as the first. Payers evaluate whether a therapy delivers enough value relative to its cost and to existing options to justify covering it. A product can be approved and clinically useful yet commercially stranded if payers decline to cover it or restrict it tightly. Understanding this early changes how a company designs its evidence, because the data that satisfies a regulator is not always the data that persuades a payer.

Evidence for payers is different

Regulators ask whether a therapy is safe and effective. Payers ask whether it is worth paying for, which is a different question. Answering it often requires evidence about real-world outcomes, cost offsets, and value relative to alternatives, sometimes captured under the heading of health economics and outcomes research. A company that builds only the evidence regulators require, and neglects the evidence payers need, can clear approval and then struggle to gain coverage. Planning both evidence streams together is a hallmark of sophisticated commercialization, a theme in how to commercialize a biotech innovation.

Coding and payment mechanics

Beyond the decision to cover, there is the machinery of how a therapy actually gets paid for. This involves codes that identify the product and procedures, payment rates, and the administrative pathways through which providers are reimbursed. These mechanics are unglamorous but decisive. A therapy without a clear payment pathway can face friction that suppresses uptake even when coverage exists in principle. Getting these details right is part of turning approval into revenue.

Pricing and reimbursement are intertwined

Price and reimbursement cannot be set independently. A price too high invites payer resistance and access restrictions, while a price too low cannot sustain a business that must recoup an enormous development cost, estimated at roughly 2.6 billion dollars per approved drug in 2013 terms (DiMasi, Grabowski, and Hansen, 2016). The right price balances the value delivered, what payers will accept, and the need to fund future work. This balance is one of the most consequential and contested decisions a healthcare company makes.

Why startups underestimate this

Reimbursement is underestimated because it is invisible during the science and only becomes urgent near launch, by which point the evidence and pricing strategy are largely locked in. Founders focused on the laboratory and the clinic can treat payers as a problem for later, only to find that later is too late to generate the evidence payers wanted. The cycles of capital that fund these companies also reward visible scientific milestones over invisible market-access work, which compounds the neglect (PitchBook and NVCA).

The pattern Reimbursement determines commercial success in healthcare, and underestimating it is a recurring, well-documented cause of disappointing launches.

The takeaway

For a healthcare startup, reimbursement is not a downstream detail but a core strategic question that should shape evidence generation, pricing, and commercial planning from early in development. Companies that engage payers and plan for coverage early reach patients and revenue; those that treat reimbursement as an afterthought often watch good therapies underperform. This is why great science can fail without a commercialization strategy, the subject of a companion essay on why great science fails without commercialization. For how this is navigated in practice, see the advisory practice.

Engaging payers as early as regulators

The practical remedy for the reimbursement trap is to engage payers with the same seriousness, and at the same early stage, as regulators. Just as companies seek guidance from regulators on trial design, they can seek input from payers on what evidence would support coverage, well before the pivotal trials are designed. Doing so can shape which outcomes a trial measures, which comparators it uses, and which economic data it gathers, so that the same studies that win approval also build the case for coverage. Companies that wait until after approval to think about payers often find that the trials are already complete and the necessary evidence was never collected. Early payer engagement does not guarantee favorable coverage, but it dramatically improves the odds and avoids the worst outcome, an approved therapy with no viable market. This dual-track approach, satisfying regulators and payers in parallel rather than in sequence, is a defining feature of companies that commercialize successfully, and it connects directly to the strategic discipline described in how to commercialize a biotech innovation.

Reimbursement varies by market and over time

One further complication is that reimbursement is not a single decision but a patchwork that varies across payers, regions, and time. A therapy covered generously by one payer may be restricted by another, and coverage policies evolve as new evidence and competing products emerge. For a startup, this means market access is an ongoing effort rather than a one-time achievement, requiring continued evidence generation and engagement after launch. It also means that financial models built on optimistic, uniform assumptions about coverage can mislead investors and founders alike. A realistic plan accounts for the variation and the lag, building the evidence and relationships needed to expand coverage over time. This long, uneven path to broad reimbursement is one more reason that commercialization must be planned as a sustained campaign, consistent with the discipline in how to commercialize a biotech innovation.